$ARTL

Artelo Biosciences (ARTL) reported that its drug ART27.13 achieved 20% weight loss in obese mice, matching semaglutide's results. Combined with semaglutide, weight loss doubled to 40%. ART27.13 showed no effect in lean mice, suggesting potential as an obesity treatment. The company plans to explore partnerships based on these findings.

Artelo Biosciences (ARTL) announced a 1-for-9 reverse stock split, effective August 31, 2026. The split aims to increase the stock's price and improve marketability. Post-split, there will be approximately 547,774 shares outstanding. Shareholder ownership percentages remain unchanged.

Artelo Biosciences (ARTL) said it enrolled the first patient in its Phase 2 DREAM trial of ART27.13, an oral once-daily cannabinoid-receptor agonist for glaucoma or ocular hypertension. The company expects interim results later this year. ART27.13 was originally developed by AstraZeneca and is also in a Phase 2 CAReS trial. ARTL last traded at $0.72.

ARTELO BIOSCIENCES, INC. (ARTL) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. artl_8k.htm 0001621221 false 0001621221 2026-07-17 2026-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 D

Artelo Biosciences (ARTL) reported positive nonclinical results for ART27.13 in a paclitaxel-induced peripheral neuropathy model. Repeated dosing reduced pain-related behaviors in male and female animals. ART27.13 is in Phase 2 for cancer-related anorexia cachexia syndrome, where interim CAReS data showed weight and activity improvements and safety at up to 1300 µg/day. ARTL shares trade around $1.04.

Artelo Biosciences (ARTL) reported encouraging nonclinical data for ART27.13 in neuropathic pain models tied to cancer supportive care. In paclitaxel-induced peripheral neuropathy animals, repeated dosing reduced neuropathic pain-related behaviors in both sexes. The stock was $1.032 on Nasdaq, down 4.41%.

Artelo Biosciences (Nasdaq: ARTL) reported nonclinical results for ART27.13, a peripherally restricted cannabinoid agonist, in a paclitaxel-induced peripheral neuropathy model. Repeated dosing reduced neuropathic pain behaviors in male and female animals. The company links this to interim Phase 2 CAReS data in cancer anorexia cachexia syndrome, citing weight and lean mass improvements and a favorable safety profile.

Artelo Biosciences (Nasdaq: ARTL) reported preclinical mouse data from Stony Brook University showing its FABP5 inhibitor ART26.12 alleviated neuropathic pain after spinal cord injury. The company says results included reduced mechanical hypersensitivity, fewer spontaneous pain behaviors, suppressed nociceptor hyperexcitability, and improved outcomes after oral dosing. ART26.12 is in Phase 1.

Artelo Biosciences (Nasdaq: ARTL) reported positive preclinical data for ART26.12, its FABP5 inhibitor, in a mouse model of spinal cord injury–induced neuropathic pain. According to the company, FABP5 inhibition reduced mechanical hypersensitivity and spontaneous pain behaviors, suppressed nociceptor hyperexcitability, and improved outcomes after oral dosing; results were presented at the 2026 International Cannabinoid Research Society symposium.

Artelo Biosciences (ARTL) is terminating its at-the-market (ATM) equity offering agreement with R.F. Lafferty, effective May 18, 2026. The company utilized only a small fraction of the $6.5 million facility, raising approximately $451,527. This decision suggests a shift in Artelo's financing strategy, potentially exploring alternative funding sources given its weak financial performance and analyst sentiment.